leadf
logo-loader
AIM:SLN

Silence Therapeutics PLC

Receive alerts
Market:
AIM
Market Cap:
£325.09 m
Price
392.00 GBX
Change
1.82%
52 weeks high
646.50
52 weeks low
298.00

In brief

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need.

Our proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Using our RNAi-directed platform technologies, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. We are currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron overload disorders, and complement-mediated disorders.

Snapshot

  • AstraZeneca deal is worth up to US$1.4bn
  • Deals also with Mallinckrodt and Takeda
  • Heart drug to file for IND this year